Pregabalin Capsule
Product Images NDC 70518-3345

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-3345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Pregabalin 150mg 70518 3345 01)

Packaging label for Pregabalin 150 mg oral capsules. Contains 90 capsules in the package, labeled as Schedule C-V and Rx only. Manufactured by Novadoz Pharmaceuticals LLC and repackaged by RemedyRepack Inc. Includes storage instructions and a QR code. The label provides NDC 70518-3345-01 and reminds to keep medication out of reach of children.*

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin 150 mg oral capsule label with a quantity of 60 capsules. Label shows proprietary and generic name Pregabalin, Controlled Substance Schedule C-V, and is marked RX Only. The labeler is RemedyRepack Inc., with repackaging location in Indiana, PA. Additional details include a QR code, storage instructions, and manufacturing information from Novadoz Pharmaceuticals LLC, Piscataway, NJ.*

FDA Label Image

Equation (Pregabain Gault Equation)

A mathematical formula for calculating creatinine clearance (CLCr), which includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplication factor of 0.85 for female patients.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin dosed at 25 mg, 100 mg, and 200 mg three times a day, compared to placebo. Higher Pregabalin doses show greater patient improvement, with curves declining from high to low percent of patients improved as the percent improvement in pain increases.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier style plot comparing the percent of patients improved over increasing percentages of pain improvement from baseline. Two lines represent treatment groups: one for Pregabalin 100 mg three times a day (dashed line) and one for placebo (dotted line). The y-axis shows percent of patients improved, and the x-axis shows percent improvement in pain from baseline, ranging from >0 to 100%.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph displaying the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares four lines representing Pregabalin dosed at 300 mg, 150 mg, and 75 mg two times a day, plus a placebo group, illustrating the relationship between dosage and patient improvement.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A Kaplan-Meier curve chart depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing their respective improvement rates over the range of pain improvement percentages.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The chart includes gridlines and vertical markers at 30 and 50 percent improvement.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart depicting responder rates (%) from two clinical studies, labeled Study E1 and Study E3. Study E1 shows responder rates for placebo and Pregabalin doses of 50 mg, 150 mg, 300 mg, and 600 mg per day (BID). Study E3 compares placebo and 600 mg per day doses of Pregabalin administered BID and TID. The vertical axis represents responder rate percentages from 0% to 60%, with numeric values atop each bar indicating specific responder percentages for each group.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph showing seizure reduction as median percent change from baseline versus dose in mg/day for different Stukly dosing regimens. The graph plots data points for Stukly E1BID, E2BID, E3BID, and E3TID at doses 0, 150, 300, and 600 mg/day with associated p-values indicating statistical significance for dose response.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 300 mg, 450 mg, and 600 mg daily doses, compared with placebo. The x-axis represents percent improvement in pain from baseline (0 to 100), and the y-axis represents percent of patients improved (0 to 100). Multiple lines correspond to each dosage and placebo, illustrating treatment effect trends.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A survival curve chart comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus placebo. The x-axis measures days, and the y-axis shows the estimated percentage of subjects without LTR, ranging from 0% to 100%. Two lines are plotted: a solid line representing Pregabalin and a dashed line representing placebo, showing differences in subject retention without LTR over time.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph showing the cumulative percent of subjects improved plotted against the percent improvement from baseline to week 12 BOCF for Pregabalin versus placebo. The y-axis represents the percent of subjects improved from 0 to 100, and the x-axis represents the percent improvement from baseline (0 to 100). The solid line represents Pregabalin and the dotted line represents placebo.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line chart comparing the percent of subjects improved from baseline to week 16 using BOCF (Baseline Observation Carried Forward) method for Pregabalin versus Placebo. The y-axis shows the percent of subjects improved (0 to 100%), and the x-axis shows the percent improvement from baseline to week 16 in 10% increments. Pregabalin shows a higher percentage of subjects improved at all improvement levels compared to Placebo.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of pregabalin showing the molecular arrangement including an amino group, a carboxyl group, and a branched aliphatic side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.